SARS CoV-2: a review of current treatment regimens

Abstract

SARS CoV-2, otherwise known as Corona virus 2019 (COVID-19) has left >300,000 dead without a definitive cure in sight. Significant research has been conducted regarding the use of currently available pharmacotherapies and multiple clinical trials are underway to bring new treatments to market. While supportive treatment remains the standard of care, additional therapeutic regimens including antivirals, monoclonal antibodies, antibiotics, anti-inflammatories, immunoenhancers, vitamins, systemic steroids, inhalants, anticoagulants, and convalescent plasma are showing promise.

Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients

“…SARS-CoV-2 treatment regimens includes uses of antivirals, systemic steroids, monoclonal antibodies, anti-inflammatory agents, antibiotics, and convalescent plasma. Hydroxychloroquine/Chloroquine is among the favorite and economically cheaper candidate involved in reducing the viral nucleic acid production and multiplication by inhibiting the binding of spike (S) protein to the ACE2 receptors that further limit the cytokine storm [ 124 ]. Similarly, other drugs including Remdesivir, Lopinavir/ritonavir and Favipiravir also showed promising approach in the management of the COVID-19-associated co-morbidities [ 124 ].…”

“…Hydroxychloroquine/Chloroquine is among the favorite and economically cheaper candidate involved in reducing the viral nucleic acid production and multiplication by inhibiting the binding of spike (S) protein to the ACE2 receptors that further limit the cytokine storm [ 124 ]. Similarly, other drugs including Remdesivir, Lopinavir/ritonavir and Favipiravir also showed promising approach in the management of the COVID-19-associated co-morbidities [ 124 ]. Monoclonal antibodies like Tocilizumab, Sarilumab, and Bevacizumab showed a beneficial approach in reduction of severity of the COVID-19 disease by restricting the IL-6 production and limiting cytokine storm [ 124 ].…”

“…Similarly, other drugs including Remdesivir, Lopinavir/ritonavir and Favipiravir also showed promising approach in the management of the COVID-19-associated co-morbidities [ 124 ]. Monoclonal antibodies like Tocilizumab, Sarilumab, and Bevacizumab showed a beneficial approach in reduction of severity of the COVID-19 disease by restricting the IL-6 production and limiting cytokine storm [ 124 ]. Another approach is based on the use of immune enhancers like intravenous gamma globulins, NK cells, interferons have also showed promising results in treatment of COVID-19 severity [ 124 ].…”

“…Monoclonal antibodies like Tocilizumab, Sarilumab, and Bevacizumab showed a beneficial approach in reduction of severity of the COVID-19 disease by restricting the IL-6 production and limiting cytokine storm [ 124 ]. Another approach is based on the use of immune enhancers like intravenous gamma globulins, NK cells, interferons have also showed promising results in treatment of COVID-19 severity [ 124 ]. Moreover, use of systemic steroids have also showed a beneficial role in lessening the disease severity [ 124 ].…”

“…Another approach is based on the use of immune enhancers like intravenous gamma globulins, NK cells, interferons have also showed promising results in treatment of COVID-19 severity [ 124 ]. Moreover, use of systemic steroids have also showed a beneficial role in lessening the disease severity [ 124 ].…”